Parvovirus B19: implications for transfusion medicine. Summary of a workshop

This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients othe...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2001-01, Vol.41 (1), p.130-135
Main Authors: Brown, Kevin E., Young, Neal S., Alving, Barbara M., Barbosa, Luiz H.
Format: Article
Language:English
Subjects:
and Blood Institute
Animals
B19 = human B19 parvovirus
Blood - virology
Blood Transfusion
Humans
Lung
NHLBI = National Heart
NHLBI = National Heart, Lung, and Blood Institute
Parvoviridae Infections - diagnosis
Parvoviridae Infections - physiopathology
Parvoviridae Infections - prevention & control
Parvovirus - immunology
Parvovirus - isolation & purification
SCD = sickle cell disease
SD = solvent/detergent-treated
SPV = simian parvovirus
United States
United States Food and Drug Administration
Viral Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This 1-day workshop showed that the infectivity of B19 DNA in donor blood and the neutralizing action of different antibodies present in the donated blood are not yet fully understood. It is possible that B19-induced anemia and reticulocytopenia are not being recognized in transfused recipients other than those in specific risk groups. The testing of blood components for any infectious agent is usually clinically driven, and, if B19 NAT were recommended at the present time in other than plasma products, a CMV-like model might prove appropriate; that is, virus screening would be performed on blood components destined for high-risk groups only. Currently, there is insufficient evidence to recommend universal testing, especially for single units. Workshop participants recommended that basic research continue in the scientific areas addressed. If clinical trials were to be developed, participants recommended that they include special risk groups such as seronegative pregnant women and children with malignancies who are receiving chemotherapy.
ISSN:0041-1132
1537-2995
DOI:10.1046/j.1537-2995.2001.41010130.x